Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

N2B-patch

Financiado

Cerrado

Nose to Brain Delivery of Antibodies via the Olfactory Region for the Treatment...

Nose to Brain Delivery of Antibodies via the Olfactory Region for the Treatment of Multiple Sclerosis Using Novel Multi functional Biomaterials Combined with a Medical Device The overall aim of N2B-patch is the development of a new innovative N2B drug delivery technology based on the synthesis of a biomaterial-based innovative galenic formulation that will be applied with the aid of a novel medical dev... ver más

30/06/2021

Fraunhofer

6M€

Presupuesto del proyecto: 6M€

Líder del proyecto

FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANG... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 13 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-06-30

NMBP-09-2016: Biomaterials for diagnosis and trea...

I+D

Cerrada hace 9 años

0% 82% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

13 Participantes

Fraunhofer

783.10K€ | Lider

DENA DESARROLLOS

263.24K€ | Participante

UNIVERSITAET BERN

653.59K€ | Participante

LGI

291.25K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

BUCCAL-PEP Development of a multifunctional biomaterial patch for bucca... 4M€ Cerrado

RTI2018-095041-B-C33 SISTEMAS DE LIBERACION DE FARMACOS BASADOS EN POLIMEROS AVAN... 91K€ Cerrado

Net2Gel Double network hydrogels for topical drug delivery applicati... 185K€ Cerrado

SupraCarrier Supramolecular hydrogels as local controlled drug delivery c... 150K€ Cerrado

BIOTRANSOS Design and evaluation of a bioadhesive film with easy peelin... 45K€ Cerrado

SME-2016-0871-1 Transparent Bioadhesive Gels (TBGs): Innovative Vehiculizati... 72K€ Cerrado

Duración del proyecto: 55 meses Fecha Inicio: 2016-11-09
Fecha Fin: 2021-06-30

Líder del proyecto

FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANG... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 6M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The overall aim of N2B-patch is the development of a new innovative N2B drug delivery technology based on the synthesis of a biomaterial-based innovative galenic formulation that will be applied with the aid of a novel medical device equipped with a container closure system (CCS) as a hydrogel patch to the nasal olfactory region for the chronic treatment of MS. The galenic formulation will consist of drug loaded biodegradable polymer particles (e.g., chitosan, polylactic-co-glycolic acid, PLGA) embedded into a biodegradable hydrogel matrix (e.g., hyaluronic acid (HA)-based) to be deposited as a patch onto the olfactory region. A pH-sensitive, mucoadhesive particle coating (e.g., chitosan, chitosan derivatives) will ensure an environment-specific adhesion to the olfactory epithelium. This novel technology will largely enhance the controlled and sustainable delivery of drugs and increase the drug bioavailabilty to the CNS. NogoA antagonist NG-101 will be used as an active pharmaceutical ingredient (API). Proof of concept studies and initial clinical data have proven the enormous potential of blocking NogoA for spinal cord remyelation and axonal integrity. However, monoclonal antibodies (mAb) like NG-101, do not sufficiently cross the BBB. The sustainable and controlled release of NG-101 to the CNS will be achieved via the transport of embedded polymer particles to the olfactory epithelium, the subsequent release of API and permeation through the olfactory region, the only part of the nasal epithelium which is in direct contact with the brain. The direct transport route from the nasal cavity to the brain, bypassing the BBB, offers an exciting mode of central nervous system (CNS) drug delivery not only for demyelinating disorders but also for other CNS indications, e.g., stroke, neurodegenerative diseases or tumours. The proposed new innovative N2B drug delivery platform is a practical, safe, and minimally invasive technology. It will be exploited for NG-101 and has the potential to be implemented with other APIs with a low CNS bioavailability.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores